Literature DB >> 12180841

Activation of complement pathways in xenotransplantation: an in vitro study.

Alexander J Walpen1, Paul Mohacsi, Caroline Frey, Anja Roos, Mohamed R Daha, Robert Rieben.   

Abstract

Pig-to-human xenotransplantation faces the problem of hyperacute graft rejection due to the presence of human naturally occurring antibodies against the disaccharide Galalpha1-3Gal (anti-Gal antibodies) expressed on pig endothelium. Antibody-mediated complement activation is usually referred to as classical pathway activation. In this study we examined if the alternative complement pathway is also directly activated through anti-Gal antibodies or if the classical pathway is indispensable. We therefore developed a hemolysis test with rabbit erythrocytes (E), which have an activating surface for the alternative complement pathway and express abundant amounts of Galalpha1-3Gal, and used this assay in addition to the standard complement tests CH50 and AP50. In this rabbit E CH50 (RECH50) assay we were able to study activation of both major complement pathways simultaneously. FACS analysis was used to trace complement and antibody deposition on rabbit E. Anti-Gal depletion of human serum by immunoabsorption revealed a 65% reduction of rabbit E hemolysis in the RECH50 test (value before absorption: 28 +/- 5.8, after absorption: 9.9 +/- 2.8, P<0.001), but only a 35% reduction of lysis in the AP50 test (AP50 before 11.3 +/- 2.1, after 7.4 +/- 2.0, P<0.002). Repletion with purified anti-Gal fully restored hemolysis in both assays. Serum depleted of Clq showed a reduced lysis of rabbit E as compared to normal human serum; this effect increased with higher serum dilutions. The reciprocal picture, i.e. less effect on hemolysis with increasing dilution, was seen with factor D depleted serum. Comparison of the RECH50 values with the AP50 values revealed an 8.4-fold increase of lysis in the RECH50 test, in which both complement pathways are running. By FACS analysis, complement deposition on rabbit E was determined and components of the classical pathway were found, especially in sera where the alternative pathway was disrupted. We conclude that in our model anti-Gal induce lysis via both classical and alternative complement pathways, but that the alternative pathway activation is of minor importance. In addition, we saw that with higher serum dilutions, the classical pathway (i.e. anti-Gal-mediated lysis) takes a predominant role in lysing the rabbit E. As anti-Gal-mediated activation of the alternative complement cascade seems of minor importance based on our results, and as there are only few surfaces in transplanted organs that would favor the alternative pathway to be executed, the specific inhibition of early steps of the classical pathway appears as a realistic strategy in pig-to-primate xenotransplantation that-to the benefit of the patient-leaves the mainly anti-bacterial defense by the alternative pathway intact.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180841     DOI: 10.1016/s0966-3274(02)00081-3

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  3 in total

1.  Effect of hyperkalemia and hemolysis caused by hyperacute rejection on cardiac function in pig to human ex vivo xenogeneic cardiac perfusion model.

Authors:  Jun Seok Kim; Hak-Mo Lee; Byoung Chol Oh; Hong-Gook Lim; Jeong Ryul Lee
Journal:  Korean Circ J       Date:  2011-03-31       Impact factor: 3.243

2.  Effect of membrane-bound complement regulatory proteins on tumor cell sensitivity to complement-dependent cytolysis triggered by heterologous expression of the α-gal xenoantigen.

Authors:  Yu Wang; Juan Liao; Ya-Jun Yang; Zhu Wang; Feng Qin; Sheng-Ming Zhu; Hong Zheng; Yan-Ping Wang
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

3.  Characterizing the Mechanistic Pathways of the Instant Blood-Mediated Inflammatory Reaction in Xenogeneic Neonatal Islet Cell Transplantation.

Authors:  David Liuwantara; Yi Vee Chew; Emmanuel J Favaloro; Joanne M Hawkes; Heather L Burns; Philip J O'Connell; Wayne J Hawthorne
Journal:  Transplant Direct       Date:  2016-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.